TY  - GEN
AU  - Tyrrell,C J
AU  - Denis,L
AU  - Newling,D
AU  - Soloway,M
AU  - Channer,K
AU  - Cockshott,I D
TI  - Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group
SN  - 0302-2838
PY  - 1998///0407
KW  - Acid Phosphatase
KW  - blood
KW  - Androgen Antagonists
KW  - pharmacokinetics
KW  - Anilides
KW  - administration & dosage
KW  - Antineoplastic Agents
KW  - Dose-Response Relationship, Drug
KW  - Estradiol
KW  - Follicle Stimulating Hormone
KW  - Humans
KW  - Liver Function Tests
KW  - Luteinizing Hormone
KW  - Male
KW  - Neoplasm Invasiveness
KW  - pathology
KW  - Neoplasm Metastasis
KW  - Neoplasm Staging
KW  - Nitriles
KW  - Prostate-Specific Antigen
KW  - Prostatic Neoplasms
KW  - Testosterone
KW  - Tosyl Compounds
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Controlled Clinical Trial; Journal Article
UR  - https://doi.org/10.1159/000019526
ER  -